BRIEF-FDA Grants Priority Review For Pfizer's Talzenna Plus Xtandi For The Treatment Of Metastatic Prostate Cancer

Pfizer Inc.

Pfizer Inc.

PFE

0.00

July 22 (Reuters) - Pfizer Inc PFE.N:

  • FDA GRANTS PRIORITY REVIEW FOR PFIZER’S TALZENNA PLUS XTANDI FOR THE TREATMENT OF METASTATIC PROSTATE CANCER

  • PFIZER - FDA SETS PDUFA ACTION DATE FOR TALZENNA PLUS XTANDI IN Q4 2026

Source text: ID:nBw8mMBS9a

Further company coverage: PFE.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.